Rafferty Asset Management
BCAB icon

Rafferty Asset Management’s BioAtla BCAB Stock Holding History

Rafferty Asset Management’s Portfolio BCAB Stock Details BCAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,662
Closed -$1.63M – 1225
2021
Q4 		$1.63M Buy
1,662
+866
+109% +$1.11M 0.01% 734
2021
Q3 		$1.17M Buy
796
+287
+56% +$559K 0.01% 767
2021
Q2 		$1.08M Buy
+509
New +$1.15M 0.01% 857

Other funds holding BCAB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Rafferty Asset Management's BCAB Position: Q1 2022 in Review

Rafferty Asset Management sold out of BioAtla (BCAB) in Q1 2022, closing a stake of 1,662 shares — an estimated $1.63M sold.

Rafferty Asset Management first reported a position in BCAB in Q2 2021 and held it in 3 quarters. The position peaked at $1.63M in Q4 2021. 97 funds tracked by Wall St. Rank hold BCAB as of Q1 2022.

  • Rafferty Asset Management reported no remaining BioAtla position as of Q1 2022 after selling out during the quarter.
  • Rafferty Asset Management sold 1,662 BioAtla shares in Q1 2022, an estimated $1.63M.
  • Rafferty Asset Management first reported a position in BioAtla in Q2 2021 and held it in 3 quarters.
  • Rafferty Asset Management's BioAtla position peaked at $1.63M in Q4 2021.
  • 97 funds tracked by Wall St. Rank held BioAtla as of Q1 2022.

Based on Rafferty Asset Management's 13F filing for Q1 2022, filed 13 May 2022.